Business Context and Reporting Period
This Form 8-K Current Report was filed by Amphastar Pharmaceuticals, Inc. on June 19, 2019. The filing reports a material event occurring on the same date regarding the resolution of pending litigation.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is a one-time settlement payment.
- Settlement Payment: $59.9 million to be received from Momenta Pharmaceuticals Inc. and Sandoz Inc.
- Payment Deadline: No later than July 2, 2019.
Material Changes
The primary material change is the execution of a settlement agreement with Momenta Pharmaceuticals Inc. and Sandoz Inc. (collectively "Momenta/Sandoz"). Under the terms of this agreement:
- Momenta/Sandoz will pay Amphastar $59.9 million.
- Both parties will submit stipulations to dismiss all pending litigation between them.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the settlement. The resolution of litigation removes the uncertainty associated with the pending legal disputes with Momenta/Sandoz. No forward-looking guidance, risk factors, or contingencies beyond the settlement terms are detailed in this specific filing.
Investor Verification Checklist
- Verify the receipt of the $59.9 million settlement payment by the July 2, 2019 deadline.
- Confirm the formal dismissal of all pending litigation with Momenta/Sandoz via court stipulations.
- Review the full text of the settlement agreement (referenced as Exhibit 99.1) for any non-monetary terms or future obligations not summarized in the 8-K.
- Assess the impact of the settlement on the company's upcoming quarterly earnings and cash flow position.